DGAP-News: Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the year 2010 and will be proposed to become a member of the board of directors
(firmenpresse) - Cytos Biotechnology AG / Change of Personnel
22.03.2010 17:45
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Schlieren (Zurich), Switzerland, March 22, 2010 - Cytos Biotechnology Ltd
(SIX:CYTN) informs that Jakob Schlapbach (59) wishes to make use of the
possibility of early retirement and plans to resign from his operational
role as CFO of Cytos Biotechnology Ltd during the year 2010. To secure his
further valuable support and long years of experience, Jakob Schlapbach
will be proposed at the forthcoming annual general meeting for the election
to the board of directors. A search for a new CFO has been initiated.
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 83 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'will', 'intended', or other similar
expressions. These forward-looking statements are subject to a variety of
significant uncertainties, including scientific, business, economic and
financial factors, and therefore actual results may differ significantly
from those presented. There can be no assurance that any further
therapeutic entities will enter clinical trials, that clinical trial
results will be predictive for future results, that therapeutic entities
will be the subject of filings for regulatory approval, that any drug
candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner(at)cytos.com
Website: www.cytos.com
22.03.2010 17:45 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
WKN: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in
Frankfurt; Foreign Exchange(s) SIX
End of News DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2010 - 12:45 Uhr
Sprache: Deutsch
News-ID 1011720
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 117 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the year 2010 and will be proposed to become a member of the board of directors
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
